Search Bar & Filters
Found 11 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating new treatment options for metastatic cervical cancer, a condition where cancer has spread from the cervix to other parts of the body. This study focuses on the safety and effectiveness of combining sacituzumab tirumotecan sac-TMT, pembrolizumab, and bevacizumab, compared to standard treatments. The research aims to understand how well these medicines work together and whether they help people live longer or delay cancer progression. The study has two parts. In Part 1, eligible participants receive sac-TMT with pembrolizumab and bevacizumab to assess safety. In Part 2, all participants first undergo standard induction treatment with pembrolizumab, paclitaxel, and cisplatin or carboplatin, with optional bevacizumab. Those whose cancer does not worsen are randomized to receive either pembrolizumab alone or sac-TMT plus pembrolizumab, with optional bevacizumab for maintenance treatment. Treatments are given by intravenous infusion at specified doses and schedules over several months. Participants will be closely monitored throughout the study with regular visits to assess safety, cancer progression, and quality of life. Researchers will track adverse events, treatment tolerability, progression-free survival, and overall survival. Quality of life questionnaires and physical functioning assessments are included to understand the impact of treatment. The study duration may extend up to approximately 69 months for safety follow-up, with various outcome measures evaluated at set intervals.
Actively Recruiting
Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.
Actively Recruiting
Researchers are evaluating treatments for patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated breast cancer that is locally advanced or metastatic. This phase III, global, randomized, open-label study compares the effectiveness and safety of inavolisib combined with fulvestrant versus alpelisib combined with fulvestrant. Participants have experienced disease progression during or after therapy with cyclin dependent kinase 46 inhibitors combined with endocrine therapy. Participants receive study drugs in repeated 28-day cycles. Inavolisib is taken orally once daily at 9 mg on days 1 to 28 of each cycle, while fulvestrant is administered at 500 mg on days 1 and 15 of the first cycle and day 1 of subsequent cycles. The comparator group receives alpelisib at 300 mg orally once daily plus fulvestrant on the same schedule. A substudy evaluates the effect of inavolisib plus fulvestrant on the metabolism of certain enzyme substrates by administering midazolam, omeprazole, and bupropion on specified days within the first cycle. Participants undergo regular assessments including tumor evaluations per RECIST criteria, blood tests, and monitoring of drug levels. The primary outcome measures progression-free survival assessed by independent review up to approximately 64 months. Secondary outcomes include overall survival, response rates, quality of life, and safety events monitored up to about 85 months. The study includes frequent visits during treatment cycles and follow-ups to evaluate side effects and long-term outcomes.
Actively Recruiting
Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.
Actively Recruiting
Healthy Volunteer
Researchers are investigating new medicines to prevent Human Immunodeficiency Virus Type 1 HIV-1 infection, focusing on women aged 16 to 30 years who are at risk. The study aims to compare the effectiveness and safety of taking MK-8527 once a month against a standard daily pre-exposure prophylaxis PrEP regimen. This phase 3 trial is designed to evaluate if MK-8527 can better prevent HIV-1 infection and how well participants tolerate this medication. Participants will be randomly assigned to one of two groups. One group will take 11 mg of MK-8527 once monthly and a daily placebo matching the standard PrEP medication. The other group will take the daily standard PrEP drugs Emtricitabinetenofovir disoproxil FTCTDF and a monthly placebo matching MK-8527, both for up to approximately two years. After this period, all participants will receive open-label FTCTDF daily for an additional 28 days. During the study, participants will undergo regular monitoring to track new HIV-1 infections, any adverse events, and reasons for discontinuing the study drug due to side effects. The safety and tolerability of MK-8527 will be assessed over the approximately two-year treatment period. The research team will collect data on these outcomes to understand the benefits and risks of MK-8527 as a preventive option for HIV-1 infection.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of inavolisib combined with Phesgo compared to placebo with Phesgo as maintenance treatment after initial therapy in people with untreated HER2-positive advanced breast cancer that has a PIK3CA mutation. This phase III trial focuses on how well the treatments control the disease and their side effects. Participants first receive induction therapy with Phesgo plus taxane-based chemotherapy. Afterward, they receive maintenance therapy with either inavolisib plus Phesgo or placebo plus Phesgo in 21-day cycles. Phesgo is given by subcutaneous injection every 3 weeks, while inavolisib or placebo tablets are taken daily on days 1 to 21 of each cycle. Optional endocrine therapy may also be provided according to standard care. During the study, participants undergo regular assessments including tumor evaluations, heart function tests, laboratory tests, and quality of life questionnaires. Researchers monitor progression-free survival up to about 40 months and overall survival and other outcomes up to approximately 111 months. Participants are followed closely for adverse events and drug levels. The total study duration may extend up to nearly 10 years, with visits scheduled throughout treatment and follow-up periods.
Actively Recruiting
Researchers are evaluating nurse-led treatment for rifampicin-resistant tuberculosis RR-TB in primary care clinics compared to standard physician-led treatment at district hospitals in South Africa. This multi-site, cluster randomized trial aims to assess treatment outcomes, safety, and patient costs over five years. The study also explores how this approach affects HIV co-infected patients and addresses the high costs and access barriers associated with hospital-based care. Participants will receive RR-TB treatment either through nurses available once or twice weekly at primary care clinics or through physicians at hospital outpatient sites. Nurse availability will rotate between clinics to mirror physician duties. The trial will compare the two approaches for treatment success, safety events, and catastrophic costs exceeding 20% of household income. Secondary goals include evaluating timing for treatment initiation, symptom resolution, provider adherence, and cost-effectiveness. During the study, participants will be closely monitored through laboratory tests, clinical assessments, and cost tracking over 12 months. Key outcomes include treatment success at six months, severe adverse events within a year, and patient cost burdens. The study involves regular evaluations of dosing adjustments and HIV-related treatment milestones. Participation spans from initial diagnosis through a year of follow-up, with blinded analysis and safety reviews to ensure data integrity.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating an expanded social network recruitment to HIV testing E-SNRHT intervention in South Africa to address the challenge of locating undiagnosed HIV cases and reducing HIV-related stigma. This study focuses on increasing HIV testing among men, who are less likely to seek testing, by encouraging peer recruitment beyond risk partners to include any social contacts. The study is a site-randomized trial involving 32 Department of Health clinics in KwaZulu-Natal, comparing E-SNRHT to usual care to assess its impact on testing rates, stigma, social support, and treatment outcomes. The intervention recruits newly diagnosed HIV-positive individuals seeds from clinics assigned to the E-SNRHT condition, who receive education about HIV transmission and are asked to recruit members of their expanded social networks for HIV testing. These network members are then tested and referred to treatment if positive or to follow-up testing if negative. The study uses recruitment coupons to maintain confidentiality and extends recruitment to secondary network members through a two-step process. Control clinics provide standard HIV testing and care without the expanded recruitment. Participants complete baseline interviews covering demographics, behaviors, stigma, and social support, with follow-up interviews at six months to track HIV-related behaviors and treatment outcomes. The study includes qualitative interviews with a subset to explore experiences of peer recruitment and stigma. Researchers will collect clinic data on ART initiation and viral suppression, monitor implementation fidelity, and evaluate intervention effects on male testing rates, new HIV diagnoses, stigma, social support, and HIV care cascade outcomes over the study period ending in 2027.
Actively Recruiting
Researchers are evaluating a health system strengthening intervention designed to support people living with severe mental illness SMI in South Africa. This study aims to determine the feasibility, appropriateness, and limited efficacy of a co-developed program to reduce hospital readmissions following acute psychiatric hospitalization. The research focuses on addressing the cycle of readmission by improving community-based care in a low-resource setting, building on partnerships and government collaboration in the uMgungundlovu District. The intervention includes multiple components improved referral pathways across healthcare levels psychosocial rehabilitation programs delivered by multidisciplinary teams and registered counselors refresher training for primary healthcare clinicians a community mental health education and detection toolkit for outreach teams and a Household Champion program to empower caregivers. Participants are randomly assigned to receive either this full intervention package or standard care with improved hospital-level referral and discharge processes. Participants will be monitored for 4 months after hospital discharge. Assessments include hospital readmission rates, recovery scores, internalized stigma, and treatment adherence, measured through questionnaires and medical records. Researchers will also collect qualitative data on the interventions acceptability, demand, implementation, practicality, adaptation, integration, and potential for expansion. This combination of data will provide insight into the programs feasibility and limited efficacy in reducing psychiatric relapse in the community.
1-10 of 11
1